Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XMT-1592 in Solid Tumors Likely to Express NaPi2b
NCT04396340Phase 1Terminated
- Sponsor
- Mersana Therapeutics
- Start
- May 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of xmt-1592 in High-Grade Serous Ovarian Carcinoma (HGSOC) and non-small cell lung cancer (NSCLC) (2 arms), sponsored by Mersana Therapeutics. Primary endpoint: Maximum Tolerated Dose or Recommended Phase 2 Dose up to 36 weeks. Started May 2020; status: terminated.
02
Drugs
xmt-1592
03
Conditions
High-Grade Serous Ovarian Carcinoma (HGSOC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04396340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396340.